Member Info for Matml74

it was the largest trade of the day of 12,000 shares. 17,000 total for the day. It has been said many times but US is irrelevant.

Yes sorry. Bad maths!!

Its completely different Barry. Has nothing to do with Philips. The aerogen is the nebuliser being used in the trials.

https://www.medicalexpo.com/prod/aerogen/product-85303-748696.html

Matterhorn, The aerogel nebuliser cost is $6.50 each.

....and it continues.

"Interferon responses during SARS-CoV-2 infection demonstrate unique patterns of dysregulated expression compared to other infectious and healthy states."

"Together with prior studies4,6,9, these data demonstrate that the transcriptional landscape of the host response to SARS-CoV-2 infection is robust, can elucidate key biological mechanisms of disease, may prove useful for therapeutic drug selection..."

https://www.nature.com/articles/s41467-021-21289-y

.... and lastly governments gave AZN billions to develop this at cost vaccine. They didn’t do it all spending their own money.

Agent,

Highly unlikely. Firstly AZN is a massive pharma who can afford to do a not for profit vaccine, which by the way only applies during the pandemic. They will make fortunes on future covid vaccines.

The testing sphere is made up of small biotechs that don’t have any money. They can’t actually afford to do this as not for profit.

Secondly the gov has spent billions on Chinese crap that weren’t provide at an at cost basis.

Please can someone wake up the MHRA....

"The authors found that the cells of people with mild–moderate COVID-19 expressed a distinct set of genes whose expression depends on what are known as type I interferon proteins. Interferons, molecules that are also called cytokines, drive the expression of genes that have a role in antiviral defence.

This interferon-regulated gene-expression signature was not observed in the cells of people with severe COVID-19. "

https://www.nature.com/articles/d41586-021-00352-0

" The primary and secondary outcomes were considered discharge and mortality, respectively. The abovementioned outcomes of standard care protocol were compared with the standard care plus IFN-ß in the confirmed COVID-19 patients. Out of 356 records identified, 12 randomized clinical trial studies were selected for full-text screening. Finally, 5 papers were included in the systematic review and 3 papers in the meta-analysis. The average mortality rate was reported as 6.195% and 18.02% in intervention and control groups, respectively. Likewise, the median days of hospitalization were lower in the intervention group (9 days) than the control group (12.25 days). According to meta-analysis, IFN-ß was found to increase the overall discharge rate (RR = 3.05; 95% CI: 1.09-5.01). Our findings revealed that early administration of IFN-ß in combination with antiviral drugs is a promising therapeutic strategy against COVID-19."

https://pubmed.ncbi.nlm.nih.gov/33587164/

Yes the extra shares contribute the same amount of profit either way. Better off not paying the tax.

Thanks for the update Hull. That is brilliant news for him.

You had an interview last week FFS. Sell up if you can't handle it.

Disclaimer: The AffiDxTM SARS-Cov-2 rapid antigen test is not currently available for sale in the United States............................ YET!

Ellume - "Studies of the Ellume demonstrated a sensitivity of 96% and specificity of 100% of in symptomatic individuals, while performance in asymptomatic individuals was 91% sensitivity and 96% specificity."

US contract - $US232 million

Surely the Cytiva tie up will ensure we get a slice of the US action.

Tyla. This is also relevant.

"The ACTIV-2 trial will progress from a Phase II to Phase III study if the agents show promising safety and lower Covid-19 symptoms within 28 days of receiving the drug."

So safety should be a clear tick.

I am very confident we can get through symptom scores as well.

They are different. This is the primary endpoint.

Duration of COVID-19 symptoms (Phase 2) [ Time Frame: Up to Day 28 ]
Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)

They also check to see if Coivd is detetcable every 7 days.

Are they on Activ 2 and halfway through a P3 trial? IF so YES. If not NO!

LOL. Best post of the day!

Depends on time to recruit the full 220 patients but it won't be far off. I am thinking end of March early April and this will also tie in with P2 home trial readout so high potential for EUA in April. Really not that long to wait when you consider risk reward on this share........ 50-75% downside from here OR 5x, 10x, 20x upside....

When you consider the body of evidence around covid severity and Interferons, NIH massive interest in interferons as a treatment, and the already peer reviewed dataset then this really is the opportunity of a lifetime.

Two million pound trades went through at 190p on Friday and I expect we will see some more large ones today. Volume is OK.

Once they have 220 patients filled. Shouldn't take too long.